PhRMA Foundation Faculty Starter Grant

The PhRMA Foundation Faculty Starter Grant in Translational Medicine is a private funding opportunity designed to support early-career faculty members who are beginning independent research careers at accredited United States universities. The PhRMA Foundation is a nonprofit organization focused on advancing value-based healthcare through research and education, particularly in drug discovery, delivery, and translational science. This program specifically emphasizes bridging laboratory discoveries with clinical applications to improve patient outcomes, reflecting the broader mission of translational medicine to connect bench research with real-world healthcare solutions. The primary purpose of this grant is to fund hypothesis-driven research that addresses unmet clinical needs and advances diagnostic, therapeutic, or computational approaches in human health. The program encourages proposals that translate findings from cellular, tissue, or animal studies into human-relevant systems, and that incorporate feedback from clinical outcomes back into research development. Areas of focus include precision medicine, biomarker validation, innovative clinical endpoints, computational modeling, and translational pharmacokinetics and pharmacodynamics. All projects must demonstrate a clear therapeutic hypothesis and include a plan for validation in human or human-relevant systems. Funding for this program consists of a single award of 100000 dollars for a one-year project period. The funds are administered through the recipient’s university and are restricted to research-related expenses. Allowable costs include personnel support for technicians or trainees, equipment purchases, and data acquisition. However, funds may not be used for the awardee’s salary, fringe benefits, indirect costs, or tuition. A limited portion of up to 1500 dollars may be allocated for domestic travel to professional meetings. The funding is contingent upon the awardee maintaining employment at their institution, and unspent funds must be returned at the end of the grant period. Eligibility is limited to full-time, research-intensive faculty members at PhD-granting accredited U.S. institutions who are early in their independent careers. Applicants must not have begun their faculty appointment before January 1, 2025, and must have received their terminal degree no earlier than January 1, 2017. Additional restrictions apply to applicants with substantial existing funding, particularly those holding major federal grants or awards exceeding 250000 dollars annually. Candidates must also demonstrate a strong publication record, including at least three first-author papers, and only one applicant per laboratory may apply. The application process is conducted in two stages through the ProposalCentral platform. The first stage requires submission of a letter of intent, including a biosketch, project abstract, research impact responses, and a concise project description. Selected applicants are then invited to submit a full application, which includes a detailed research plan, budget, letters of reference, and supporting documentation. The process requires coordination with collaborators and references, as well as adherence to strict formatting and submission guidelines. Key dates for the program include the opening of the application portal on April 15, 2026, and the letter of intent deadline on May 27, 2026. Invitations for full applications are expected by September 23, 2026, with final submissions due on November 18, 2026. Award notifications are anticipated in March 2027, and funding may begin as early as April 1, 2027. The program appears to follow an annual cycle, with a structured review process and defined milestones leading to final award decisions.

Ensure a clear therapeutically relevant hypothesis include human validation components and align project with unmet clinical needs and translational impact